Display options
Cite
Colosia A, Khan S, Hackshaw MD, et al. A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma. Sarcoma. 2016;2016:3597609doi: 10.1155/2016/3597609.
Colosia, A., Khan, S., Hackshaw, M. D., Oglesby, A., Kaye, J. A., & Skolnik, J. M. (2016). A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma. Sarcoma, 20163597609. https://doi.org/10.1155/2016/3597609
Colosia, Ann, et al. "A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma." Sarcoma vol. 2016 (2016): 3597609. doi: https://doi.org/10.1155/2016/3597609
Colosia A, Khan S, Hackshaw MD, Oglesby A, Kaye JA, Skolnik JM. A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma. Sarcoma. 2016;2016:3597609. doi: 10.1155/2016/3597609. Epub 2016 Jul 19. PMID: 27516726; PMCID: PMC4969544.
Copy Download .nbib Format: NLM
Share it on

Sarcoma. 2016;2016:3597609. doi: 10.1155/2016/3597609. Epub 2016 Jul 19.

A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma.

Sarcoma

Ann Colosia, Shahnaz Khan, Michelle D Hackshaw, Alan Oglesby, James A Kaye, Jeffrey M Skolnik

Affiliations

  1. Market Access and Outcomes Strategy, RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, Durham, NC 27709, USA.
  2. US Health Outcomes, Oncology, GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 19112, USA.
  3. Epidemiology, RTI Health Solutions, 1440 Main Street, Suite 310, Waltham, MA 02451, USA.
  4. US Medical Affairs, Oncology, GlaxoSmithKline, 5 Crescent Drive, Philadelphia, PA 19112, USA.

PMID: 27516726 PMCID: PMC4969544 DOI: 10.1155/2016/3597609

Abstract

This systematic literature review describes adverse events (AEs) among patients with soft tissue sarcoma (STS) who received second-line or later anticancer therapies. Searches were conducted in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for studies of adults with advanced or metastatic STS who received systemic anticancer therapy before enrollment in a randomized-controlled trial of pazopanib, another targeted cancer agent, or cytotoxic chemotherapy. Of 204 publications identified, seven articles representing six unique studies met inclusion criteria. Additional safety results for pazopanib were identified on ClinicalTrials.gov. Hematologic toxicities were common with all therapies evaluated (pazopanib, trabectedin, dacarbazine ± gemcitabine, gemcitabine ± docetaxel, cyclophosphamide, and ifosfamide). Studies differed in AE type, timing of assessment, and outcomes reported, although patient populations and AE assessment timing were relatively similar for pazopanib and trabectedin. AEs that were more common with trabectedin than pazopanib were anemia, neutropenia, nausea/vomiting, and elevations in aspartate aminotransferase and alanine aminotransferase. An AE that was more common with pazopanib than trabectedin was anorexia. Only the pazopanib study reported AE frequencies versus placebo. A planned meta-analysis was not feasible, as there was no common comparator. More well-designed studies that include common comparators are needed for comparison of safety effects among treatments for STS.

References

  1. J Clin Oncol. 2011 Jun 20;29(18):2528-33 - PubMed
  2. Lancet. 2016 Apr 16;387(10028):1629-37 - PubMed
  3. J Clin Oncol. 2009 Sep 1;27(25):4188-96 - PubMed
  4. J Clin Oncol. 2009 Jul 1;27(19):3148-53 - PubMed
  5. Invest New Drugs. 2011 Jun;29(3):481-8 - PubMed
  6. Lancet. 2012 May 19;379(9829):1879-86 - PubMed
  7. J Clin Oncol. 2007 Jul 1;25(19):2755-63 - PubMed
  8. Eur J Cancer Clin Oncol. 1987 Mar;23(3):311-21 - PubMed
  9. J Clin Oncol. 2009 Jul 1;27(19):3154-60 - PubMed
  10. Lancet Oncol. 2015 May;16(5):531-40 - PubMed
  11. Cancer. 2015 Sep 1;121(17):2933-41 - PubMed
  12. BMJ. 2009 Jul 21;339:b2535 - PubMed
  13. Cancer Chemother Pharmacol. 1993;31 Suppl 2:S180-4 - PubMed
  14. BMJ. 2009 Jul 21;339:b2700 - PubMed
  15. Ann Oncol. 2012 Mar;23(3):777-84 - PubMed
  16. J Clin Oncol. 2016 Mar 10;34(8):786-93 - PubMed
  17. J Clin Oncol. 2016 Jul 1;34(19):2294-302 - PubMed
  18. Eur J Cancer. 2002 Dec;38(18):2397-406 - PubMed
  19. Cancer Chemother Pharmacol. 1986;18 Suppl 2:S13-6 - PubMed
  20. Cleve Clin J Med. 2010 Mar;77 Suppl 1:S23-6 - PubMed
  21. BMC Cancer. 2013 Aug 13;13:385 - PubMed
  22. Invest New Drugs. 2012 Apr;30(2):729-40 - PubMed
  23. J Clin Oncol. 2010 Feb 20;28(6):1061-8 - PubMed
  24. Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9 - PubMed
  25. Oncologist. 2012;17(9):1213-20 - PubMed

Publication Types